Dermatology’s growing focus on skin longevity demands clear definitions, validated outcomes, and rigorous evidence beyond anti-aging claims.
Blog|Articles|September 19, 2023
Pointers With Portela: What to Know About Ozempic
Author(s)Dustin Portela, DO
In this week’s Pointers With Portela, the 208SkinDoc discusses 5 key takeaways about Ozempic, including adverse effects and hidden risks.
Advertisement
In his most recent YouTube episode, "5 Things You Need To Know Before Taking Ozempic"
In his discussion, Portela covers:
- What is Ozempic and how does it work?
- How does Ozempic compare to Wegovy and Munjaro?
- What are the common side effects of Ozempic?
- What are the hidden risks of taking Ozempic?
- Can you drink alcohol while taking Ozempic?
- What is the difference between Ozempic and Metformin?
Opinions expressed are that of Portela and do not express the views or opinions of Dermatology Times®.
Dr Portela's social media channels:
YouTube:
2.
3.
Instagram:
X (formerly known as Twitter):
Advertisement
Related to this article
Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
Tina Bhutani-Jacques, MD, explored how disease location, prior treatment response, and patient preference shape topical treatment decisions across 3 plaque psoriasis cases.
Benjamin Ungar, MD, moderated a recent Dermatology Times Case-Based Roundtable event on how to define severity, choose among JAK inhibitors, and monitor patients with alopecia areata.
Clinicians at a Dermatology Times Case-Based Roundtable, moderated by Chesahna Kindred, MD, debated when to escalate to oral JAK inhibitors for alopecia areata and how to counsel patients on timing, monitoring, and safety.
The joint AAD-HSF guideline issues 37 recommendations, including strong support for adalimumab, bimekizumab, infliximab, and secukinumab.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
Advertisement
Advertisement
Trending on Dermatology Times
1
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
2
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
3
Individualizing Systemic Therapy for Alopecia Areata Across Patient Cases
4
Skin Longevity Needs Evidence, Not Hype
5